Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "immunomodulatory" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-3 z 3
    Tytuł:
    The Biological Properties Of Lactoferrin
    Autorzy:
    Trybek, Grzegorz
    Metlerski, Marcin
    Szumilas, Kamila
    Aniko-Włodarczyk, Magda
    Preuss, Olga
    Grocholewicz, Katarzyna
    Wiszniewska, Barbara
    Powiązania:
    https://bibliotekanauki.pl/articles/1054782.pdf
    Data publikacji:
    2016
    Wydawca:
    Uniwersytet Szczeciński. Wydawnictwo Naukowe Uniwersytetu Szczecińskiego
    Tematy:
    antimicrobial activity
    immunomodulatory effect
    lactoferrin
    Opis:
    Lactoferrin (LF) is an iron-binding glycoprotein from the transferrin family, which has been identified in most biological fluids as secretions from exocrine glands and the content of specific granules of neutrophils. It has been reported to have numerous functions. Due to antimicrobial and anti-inflammatory activity, the lactoferrin plays significant role in host defense against infection and extreme inflammation. Recent studies have also demonstrated that LF can protect against cancer in experimental animals and has anticarcinogenic activity in many human tumors. At the cellular level, LF modulates the proliferation, differentiation, maturation, activation, migration and function of immune cells. This review presents the multifunctional roles and specific beneficial properties of lactoferrin.
    Źródło:
    Central European Journal of Sport Sciences and Medicine; 2016, 15, 3; 15-25
    2300-9705
    2353-2807
    Pojawia się w:
    Central European Journal of Sport Sciences and Medicine
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The efficacy of combination therapy with lenalidomide and dexamethasone in the treatment of relapsed multiple myeloma
    Autorzy:
    Szudy-Szczyrek, A.
    Legiec, W.
    Mańko, J.
    Gmyz, K.
    Szczyrek, M.
    Hus, M.
    Powiązania:
    https://bibliotekanauki.pl/articles/2052439.pdf
    Data publikacji:
    2015
    Wydawca:
    Akademia Bialska Nauk Stosowanych im. Jana Pawła II w Białej Podlaskiej
    Tematy:
    multiple myeloma
    immunomodulatory drugs
    maintenance therapy
    lenalidomide
    Opis:
    Multiple myeloma is a neoplastic disease which is characterised by proliferation of monoclonal plasmocytes in the bone marrow. It is the second most common hematologic cancer and it represents 1% of all cancer deaths. Despite enormous development in multiple myeloma biology and treatment over the last 30 years - it is still incurable disease with a median survival of 50 – 55 months. Currently, one of the most important goals in the treatment of multiple myeloma is to achieve long-term control of the disease, without negative impact on the patient’s quality of life. Thanks to therapeutic regimens based on new immunomodulatory drugs, this aim seems to be achievable. In this paper we present the case of a female patient living with multiple myeloma for 14 years. Initially patient was treated with standard VAD (vincristine, doxorubicin, dexamethasone) chemotherapy regimen. After a nearly complete remission of the disease, autotransplantation of hematopoietic cells was performed. One year after transplantation there was a relapse of the disease. In the treatment of relapse it was decided to use scheme based on lenalidomide and dexamethasone. After 4th cycle of treatment, a complete remission was achieved. So far, the patient received 149 cycles. In the evaluation of minimal residual disease still maintains a state of complete remission maintains. During over 12 years of treatment no complications in grade 3 and 4 of the CTCAE v.4 was observed. Currently the patient is 58 years old, she still receives lenalidomide and leads moderately active life.
    Źródło:
    Health Problems of Civilization; 2015, 09, 2; 50-54
    2353-6942
    2354-0265
    Pojawia się w:
    Health Problems of Civilization
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Innovation immunomodulatory treatment – case study of men diagnosed with relapsing-remitting multiple sclerosis (MS)
    Autorzy:
    Siudak, Martyna
    Cylke, Dominika
    Tober-Marczewska, Anna
    Powiązania:
    https://bibliotekanauki.pl/articles/1179477.pdf
    Data publikacji:
    2017
    Wydawca:
    Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
    Tematy:
    SM
    disability
    experimental
    immunomodulatory
    sclerosis multiplex
    treatment
    Opis:
    Multiple Sclerosis (MS) is a complex disease that interferes with environmental factors and genetically predisposed conditions. This is a chronic, inflammatory disease of the central nervous system in which demyelination of neural tissue occurs. It is most often the case for young people with a slightly higher prevalence among women than men. Occurrence is rising in countries far from the equator, and the highest incidence is observed in temperate white people. This disease is characterized by so-called "rolls" that can last from 24 hours to several weeks. At this time there is a sudden increase in the existing symptoms or the appearance of a new one. The first signs of the disease are often mild and tend to cease quickly. The name reflects the spread of the pathological process in various places in the nervous system as well as the spread of changes over time. Regardless of the recognized form, the effect of MS is disability and reduced quality of life, which hinders self-reliance, self-care and freedom of movement. This paper is a case study of 49-year-old patient diagnosed with relapsing-remitting MS included in the experimental program of immunomodulatory treatment.
    Źródło:
    World Scientific News; 2017, 78; 249-254
    2392-2192
    Pojawia się w:
    World Scientific News
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-3 z 3

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies